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Abstract
Predicting the clinical outcome of cancer patients based on the expression of marker genes in their tumors has received
increasing interest in the past decade. Accurate predictors of outcome and response to therapy could be used to
personalize and thereby improve therapy. However, state of the art methods used so far often found marker genes with
limited prediction accuracy, limited reproducibility, and unclear biological relevance. To address this problem, we
developed a novel computational approach to identify genes prognostic for outcome that couples gene expression
measurements from primary tumor samples with a network of known relationships between the genes. Our approach ranks
genes according to their prognostic relevance using both expression and network information in a manner similar to
Google’s PageRank. We applied this method to gene expression profiles which we obtained from 30 patients with
pancreatic cancer, and identified seven candidate marker genes prognostic for outcome. Compared to genes found with
state of the art methods, such as Pearson correlation of gene expression with survival time, we improve the prediction
accuracy by up to 7%. Accuracies were assessed using support vector machine classifiers and Monte Carlo cross-validation.
We then validated the prognostic value of our seven candidate markers using immunohistochemistry on an independent
set of 412 pancreatic cancer samples. Notably, signatures derived from our candidate markers were independently
predictive of outcome and superior to established clinical prognostic factors such as grade, tumor size, and nodal status. As
the amount of genomic data of individual tumors grows rapidly, our algorithm meets the need for powerful computational
approaches that are key to exploit these data for personalized cancer therapies in clinical practice.
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Introduction
In the past decade, several studies have used microarray gene
expression data from tumors to predict the clinical outcome of
patients (see Table S1). The tumors included breast cancer [1–5],
lung cancer [6–8], lymphomas [9–13], leukemia [14,15], and
others [16–18]. Outcome is usually measured by categorical, often
binary variables such as survival up to a certain time, recurrence of
tumor or metastasis before a certain time, or success of treatment.
Predicting such variables from gene expression levels can be
viewed as a classification problem, and the set of genes used for
prediction is commonly referred to as a signature. Accurate
outcome prediction can be used clinically to select the best of
several available therapies for a cancer patient. For instance, a low
risk patient can be advised to select a less radical therapy.
Whereas differences in gene expression between tumor and
healthy tissue or between different tumor tissues are often strong,
gene expression differences between patients with the same type of
tumor but different outcome are more subtle. For example,
distinguishing acute myeloid from acute lymphoblastic leukemia
has been demonstrated to be up to 100% accurate using only a few
genes [19–21]. In contrast, outcome prediction is a much harder
problem, with classification accuracies commonly in the range of
50–70%. It is therefore not surprising that many studies suffer
from one or several of the following three problems: (i) limited or
overoptimistic prediction accuracy, (ii) limited reproducibility, and
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For example, an early study predicting breast cancer metastasis
using 70 genes [3] was subsequently found (i) to have lower than
initially published predictive accuracy on the same or independent
data sets [22,23], (ii) to be difficult to reproduce [24], and (iii) to
have used 70 genes that can be easily replaced by 70 different but
equally predictive genes derived from the same data, questioning
the biological relevance of the particular 70 genes of the original
study [25]. Notably, predictive gene sets derived from different
studies for the same disease show almost zero overlap, questioning
their biological relevance.
To address and overcome these problems we have developed a
computational network-based strategy for outcome prediction.
Our algorithm, NetRank, couples gene expression measurements
with a network of known relationships between the genes’
products. NetRank is based on Google’s PageRank algorithm
[26]. PageRank uses the hyperlink information between web
documents to better decide which documents are the most relevant
ones. Similarly, NetRank uses biological interaction information
between genes’ products to better decide which genes are the most
relevant for outcome prediction. Such interaction information is
available in protein–protein, transcription factor–target, or gene
co-expression networks. The inclusion of network information
serves two purposes. First, gene products with many interactions
should have a higher biological relevance since they can exert a
bigger influence on a biological system. Second, considering
network neighbors can help the algorithm to ignore correlations
between expression and outcome that have no underlying
biological causality. Such correlations can arise simply by chance,
often due to the fact that microarray measurements are noisy and
that the number of samples is typically several orders of
magnitudes smaller than the number of genes investigated.
We wanted to test the NetRank idea on outcome prediction for
pancreatic cancer, for which no microarray-derived signature was
yet published. Pancreatic ductal adenocarcinoma accounts for
approximately 130,000 deaths each year in Europe and the United
States [27,28]. It has an extremely poor prognosis with a 5-year
survival rate below 2% [29,30]. Currently, only a few prognostic
factors for pancreatic cancer survival are used in the clinical
setting, among them CA 19-9, alkaline phosphatase, LDH, levels
of white blood cells, aspartate transaminase, and blood urea
nitrogen [31]. A considerable number of protein markers for
pancreatic cancer prognosis have been investigated using immu-
nohistochemistry [32]. However, the clinical value of most of these
markers remains to be determined, and also most of these markers
were found by chance or educated guesses rather than a
systematic, genome-wide approach.
The aim of our study was therefore (i) to carry out a genome-
wide screen for genes whose expression in pancreatic cancer tissue
samples reliably correlates with the patient survival time, and (ii) to
use these genes as a molecular signature for reliable survival
prediction. To this end, we collected and analyzed tissue samples
from patients with pancreatic ductal adenocarcinoma from
Germany in a multi-center study. Applying NetRank to gene
expression profiles of these samples identified seven candidate
marker genes prognostic for outcome. To assess the clinical value
of our identified marker genes, we validated them on an
independent patient cohort. We found that signatures based on
these markers were more accurate than traditional clinical
parameters and more accurate than signatures identified with
other computational approaches.
Results
We obtained gene expression profiles of sufficient quality from
30 pancreatic ductal adenocarcinoma samples of patients that
underwent surgery in German university hospitals between 1996
and 2007, hereafter referred to as the screening dataset (see
Materials and Methods for quality criteria and experimental
details). For each patient, the clinical parameters age, sex, cancer
staging according to the tumor-node-metastasis (TNM) classifica-
tion, and survival time after operation were recorded. Table 1
shows an overview of the patient characteristics. For predicting the
prognosis of a patient, we assigned patient samples to either a poor
or a good prognosis group depending on patient survival time.
Such an assignment is straightforward if the survival time is
bimodally distributed. However, such a bimodal distribution is
often absent in cancer patient survival times (see Figure S1). In
this case, a common choice is to split by the median survival time
independently of the distribution (see for example [13,33]), which
has the advantage of yielding two classes of equal size. Thus, we
defined prognosis as poor if the patient survival time was less than
the median survival time of 17.5 months, and as good otherwise.
This resulted in two prognosis groups with 15 patient samples
each. The goal was to identify a signature of genes whose
expression levels allowed to correctly predict the prognosis group
of a patient. Since we wanted the resulting signature to be
applicable in a clinical setting using immunohistochemistry
staining of the signature proteins, we opted for a signature size
in the order of five to ten genes.
Signature evaluation methodology
To identify signature genes, various state of the art methods
exist. To evaluate these methods in comparison to our own
NetRank method on the screening dataset, the following workflow
was employed (see Figure 1). After filtering out low expression
and low variance genes, *8,000 genes remained as potential
signature genes. Five different methods for ranking genes
according to their power to discriminate between the two
prognosis groups were tested: (i) fold change, as defined by the
ratio of a gene’s mean expression in one group over the other
group, (ii) the t-statistic, (iii) Pearson and Spearman rank
correlation coefficients of a gene’s expression with the survival
Author Summary
Why do some people with the same type of cancer die
early and some live long? Apart from influences from the
environment and personal lifestyle, we believe that
differences in the individual tumor genome account for
different survival times. Recently, powerful methods have
become available to systematically read genomic informa-
tion of patient samples. The major remaining challenge is
how to spot, among the thousands of changes, those few
that are relevant for tumor aggressiveness and thereby
affecting patient survival. Here, we make use of the fact
that genes and proteins in a cell never act alone, but form
a network of interactions. Finding the relevant information
in big networks of web documents and hyperlinks has
been mastered by Google with their PageRank algorithm.
Similar to PageRank, we have developed an algorithm that
can identify genes that are better indicators for survival
than genes found by traditional algorithms. Our method
can aid the clinician in deciding if a patient should receive
chemotherapy or not. Reliable prediction of survival and
response to therapy based on molecular markers bears a
great potential to improve and personalize patient
therapies in the future.
Outcome Prediction by Network-Based Ranking
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Screening dataset Validation dataset Validation dataset
Adjuvant therapy No adjuvant therapy
n% n% n%
Total number of patients 30 100 172 100 240 100
Sex
female 19 63 73 42 115 48
male 11 37 99 58 125 52
Age
Median (years) 65 65 66
Range (years) 40–82 33–81 31–85
Patient survival
1 year 17 57 104 60 146 61
2 years 9 30 38 22 83 35
3 years 6 20 12 7 54 23
4 years 3 10 4 2 32 13
5 years 0 0 3 2 15 6
Median (months) 17.5 14.4 15.5
Range (months) 5–53 1–109 1–189
Primary tumor{
p T 1 00 32 62
pT2 2 7 28 16 42 18
pT3 26 87 137 80 182 76
p T 4 27 42 94
Regional lymph nodes{
pN0 12 40 43 25 88 37
pN1 18 60 129 75 148 62
Distant metastasis
M0 29 97 152 88 182 76
M1 1 3 11 6 17 7
Histologic grade
G 1 13 74 1 7 7
G2 11 37 67 39 108 45
G3 18 60 97 56 111 46
Residual tumor
R0 24 80 119 69 167 70
R 1 3 1 04 0 2 35 7 2 4
R2 3 10 6 3 5 2
Stage grouping{
I2 7 1 1 6 1 8 8
IIA 10 33 26 15 54 22
IIB 15 50 112 65 106 44
I I I 27 32 42
IV 1 3 11 6 17 7
The screening dataset (genome-wide gene expression profiling) comprises 30 samples of surgically resected pancreatic ductal adenocarcinoma from patients without
adjuvant chemotherapy. The validation dataset (immunohistochemistry of seven marker candidates) comprises samples from 412 patients, of which 172 had received
adjuvant therapy and 240 had not. Significant differences between the adjuvant and no adjuvant therapy subgroups were found for regional lymph nodes status
(p~0:01, Fisher’s exact test) and for the stage groupings (p~0:04, Fisher’s exact test). Differences in all other variables were not significant.
{Based on postsurgical histopathological assessment (indicated by the p prefix).
{Stage was assessed by the American Joint Committee on Cancer 2006 guidelines.
doi:10.1371/journal.pcbi.1002511.t001
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PLoS Computational Biology | www.ploscompbiol.org 3 May 2012 | Volume 8 | Issue 5 | e1002511Figure 1. Monte Carlo cross-validation workflow to evaluate the accuracy of methods for ranking genes for outcome prediction.
The full dataset is a gene expression matrix with *8,000 features (the genes) as rows and 30 samples (the patients) as columns. For each patient, the
outcome (poor or good) is given (1). The dataset is randomly divided into a training and a test set (2). Within the training set, genes are ranked by
how different they are between patients with poor and good outcome (3). The most different genes are selected (4). They are used to train a machine
Outcome Prediction by Network-Based Ranking
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Microarrays) method [34], and (v) our NetRank algorithm (see
Materials and Methods for details). In addition, selecting genes
randomly was included as a control method. For each method, a
support vector machine classifier was trained using the 5–10 top
ranked genes as features. Prediction accuracy as defined as the
percentage of correctly classified samples was evaluated with
different training and test set sizes. All feature selection and
machine learning steps were subjected to Monte Carlo cross-
validation, which is a recommended and relatively un-biased
evaluation strategy [22,35] (see Figure 1 and Materials and
Methods for details).
NetRank, a network-based approach for identifying
predictive marker genes from microarray data
We introduce NetRank, a modified version of the PageRank
algorithm [36]. As employed by the Google Internet search engine,
the PageRank algorithm uses network information (hyperlinks)
between documents in the world wide web to assess the relevance of
a document. A document is important if it is highly cited by other
documents. Moreover, citations from important documents have
more weight than citations from unimportant documents. Thus, in
order to measure the relative importance of a document within the
set of all web documents, PageRank ranks a document according to
the number of highly ranked documents that point to it. Similarly,
NetRank assigns a score to a gene which is influenced by the scores
of genes linked to it. This linkage can be defined in several ways.
Morrison et al. [37] described an adaptation of PageRank which
uses networks where genes are connected if they share a Gene
Ontology annotation. Here, we employ known transcriptionfactor–
target relationships (from TRANSFAC [38]), protein–protein
interaction (from HPRD [39]), and gene co-expression (from
COXPRESdb [40]) to define three different gene–gene networks,
which were used with NetRank. NetRank first assigns as a score for
each gene the absolute correlation of its mRNA expression level
with the patient survival time in the dataset. The network is then
used to spread this correlation to its neighbors and beyond. The
genes with the highest NetRank score are then selected as signature
genes (see Materials and Methods for details).
NetRank outperforms traditional approaches
We first compared the three above mentioned networks for
NetRank and found that signatures obtained using the TRANS-
FAC transcription factor network consistently had higher predic-
tive accuracies than those using the protein interaction or the co-
expression network. We therefore decided to only use the
TRANSFAC network for NetRank in the following experiments.
For all training set sizes, signatures selected with NetRank using
the TRANSFAC transcription factor–target network showed
higher predictive accuracies than those selected by any of the
other four methods (Figure 2A). NetRank showed a maximum
accuracy of 72% (+1% standard error of the mean, s.e.m.) with a
training set of 28 samples and a signature size of 7 genes. This
compares favorably to studies in other cancers, which show
accuracies in the range of 50–70%. We found that NetRank is
especially beneficial for small training set sizes, where there is a 7%
(+0:4% s.e.m.) improvement in accuracy compared to the
Pearson correlation method.
Since many single prognostic markers for pancreatic cancer
have been described in the literature, we next asked whether
markers found with NetRank were superior to these literature
markers. To this end, 51 markers identified via a literature search
were used to train a support vector machine with different training
set sizes (see Materials and Methods and Table S2). Surprisingly,
we found that the NetRank markers showed on average a 12%
higher accuracy than the literature markers (Figure 2B).
Using NetRank, we identified seven genes (STAT3, FOS, JUN,
SP1, CDX2, CEBPA, and BRCA1) as most relevant for predicting
survival in patients with pancreatic ductal adenocarcinoma. These
seven marker candidates were validated in two ways: first, by
quantitative RT-PCR of the screening dataset to confirm the
microarray gene expression measurements, and second, by
immunohistochemical analysis of protein levels in an independent
dataset of 412 patients (the validation dataset, see Table 1).
The marker genes control the expression of many target
genes that are involved in cancer-related pathways
Of our seven markers, we found high expression to be
associated with shorter survival for STAT3, FOS, and JUN, and
high expression associated with longer survival for SP1, CDX2,
CEBPA, and BRCA1. This is in line with most previous studies.
STAT3 is a well-known oncogene and persistently activated in
many human cancers, including all major carcinomas [41]. FOS
and JUN, which constitute the AP-1 transcription factor, have
been linked to both tumor progression and suppression [42]. SP1
was reported to be associated with poor prognosis in gastric cancer
and recently also in pancreatic ductal adenocarcinoma [43,44].
BRCA1 is a DNA damage repair protein where loss-of-function
mutations typically lead to early onset of breast cancer and ovarian
cancer [45].
Figure 3A shows the direct network neighbors of the seven
candidates. The network is shown in power graph representation,
which reduces the number of edges drawn without information
loss [46]. The underlying network of regulatory relationships was
obtained from the TRANSFAC database [38]. The network
shows that the seven markers (yellow) regulate a total of 323
targets. The correlation of the expression of a gene with the
survival of the patient in the screening dataset is shown in red.
Genes with larger circles were previously described in the
literature as being associated with survival in pancreatic cancer.
The marker protein with the most regulatory interactions is the
transcription factor SP1. Some of its targets are additionally
regulated by other markers such as CEBPA, STAT3, FOS, and
JUN. One interesting module defined by the genes that are
regulated by SP1 and FOS is shown in Figure 3B. It contains
many genes already known to be associated with survival in
pancreatic cancer as well as some genes highly correlated with
survival in our data, such as HBA1, F3, CCL2, IL2, and GJA1.A
subset of this module is defined by genes that are also regulated by
JUN. This subset contains the genes IL2, TGFB1, MT2A, and
GJA1, which correlate well with survival.
Among the interaction partners of the markers, more than one-
third has been previously reported as associated with survival or
prognosis in pancreatic cancer, including PPARG, MUC4, and
SMAD3 [47,48]. A pathway analysis using KEGG [49] showed
that 91 of the interacting genes are involved in signaling pathways,
most prominently the MAPK and JAK-STAT signaling pathways.
learning classifier on the training set (5). After training, the classifier is asked to predict the outcome of the test set patients (6). The predicted
outcome is compared with the true outcome and the number of correctly classified patients is noted (7). Steps 2–7 are repeated 1,000 times, and the
resulting final accuracy is obtained by averaging over the 1,000 accuracies of step 7.
doi:10.1371/journal.pcbi.1002511.g001
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KEGG cancer pathways (see Table S3).
Two immunohistochemistry signatures predict survival
for patients with and without adjuvant therapy
To validate our findings, we analyzed protein levels of our
markers in an independent set of 412 patients (the validation
dataset, see Table 1). We wanted to test how well the proteins
encoded by the marker genes are indicative for the survival of a
patient when assessed by immunohistochemical staining of the
patient’s tumor. Using tissue microarrays, immunohistochemistry
stainings were obtained for each of the seven marker proteins
STAT3, FOS, JUN, SP1, CDX2, CEBPA, and BRCA1 for each
patient in the validation dataset (see Figure S2). The predictive
accuracies of the marker staining intensities (encoded in two levels,
low or high, see Materials and Methods) were evaluated after
training a support vector machine classifier in a leave-one-out
cross-validation procedure. The classifier predicted patients to
belong either to a low risk (good prognosis) group, or to a high risk
(poor prognosis) group. Using backward elimination, starting from
the full set of markers, markers were removed one at a time until
the accuracy of the trained classifier failed to improve. The clinical
parameters tumor size (T), regional lymph nodes (N), distant
metastasis (M), histological grade (G) and residual tumor (R) were
tested in the same manner for comparison.
Since some patients in the validation dataset received adjuvant
therapy (mostly chemotherapy with gemcitabine), and the
adjuvant therapy had an influence on survival time (although
not quite as expected, see Figure S3), we split the validation
dataset into a group of patients with and without adjuvant therapy.
Note that the decision to treat a patient with adjuvant
chemotherapy is so far not based on any molecular markers
(which was one motivation for our study). Chemotherapy is part of
the standard treatment for pancreatic cancer in Germany since
many years and is recommended for every patient. However,
patients in a reduced state of health and patients who refuse it will
not receive chemotherapy.
A signature for prognosis of patients with adjuvant
therapy. The signature with the highest predictive accuracy of
65% (68% area under the ROC curve, AUC) consisted of the
proteins STAT3, FOS, JUN, CDX2, CEBPA, and BRCA1 (see
Figure 4A and Figure S4A). The median survival time was 17
months in the predicted low-risk group and 12 months in the high-
risk group (p~0:001, logrank test). The accuracy could be further
improved by adding clinical parameters (T, N, M, G, R, see see
Table 1) to the classifier. Starting with the combination of all
protein and clinical markers and using again backward elimina-
tion, the combination of the markers STAT3, FOS, SP1, CEBPA,
and BRCA1 with the clinical parameters R, N, and M achieved
the highest prediction accuracy of 70% (69% AUC). The best
combination of clinical parameters alone was G, R, and T with an
accuracy of 61% (63% AUC).
A signature for prognosis of patients without adjuvant
therapy. Using the same approach, we developed a signature
for the subgroup of patients without adjuvant therapy. The marker
signature with the highest predictive accuracy of 60% (59% AUC)
consisted of STAT3, JUN, SP1, CDX2, and BRCA1 (see
Figure 4B and Figure S4B). The median survival was 18
months in the predicted low-risk and 13 months in the predicted
high-risk group (p~0:007, logrank test). The combination of the
markers FOS and BRCA1 with the clinical parameters G, R, and
M achieved a predictive accuracy of 65% (64% AUC). The best
combination of clinical parameters alone was G, R, N, and M with
an accuracy of 59% (64% AUC).
Signatures are superior to clinical parameters and
independently predictive of outcome. Both signatures based
on immunohistochemical staining of the tumor tissue improve
prediction of patient prognosis. Comparison of the above signature
accuracies shows that the additional predictive value of the
signature markers compared to clinical parameters is 9% for
patients with and 6% for patients without adjuvant therapy (70%
versus 61% for adjuvant, and 65% versus 59% for non-adjuvant
therapy).
To further ensure that the markers predict survival indepen-
dently from clinical parameters, we tested if there was a significant
interaction in a Cox proportional hazard model for any pair of a
marker and a clinical parameter. We did not find a significant
interaction between any marker and any clinical parameter (N, M,
G, R) used in our signatures. Hence, the markers found in our
study are independently predictive of outcome and superior to
established clinical parameters.
One important finding of our validation was that the accuracy
dropped from 72% to 65% when going from mRNA to protein
level. Two reasons are likely to contribute to this fact. First, protein
levels are known to not always correlate well with mRNA levels
[50,51]. Second, protein levels were encoded based on immuno-
histochemistry staining intensity in only two grades (low, high),
leading to a reduction of information available for the classifier
compared to the continuous microarray measurements.
Comparison with other studies
The accuracies of our signatures are comparable to those found
in other cancer studies. Stratford et al. [18] found six genes
differentially expressed in tumors from pancreatic cancer patients
with localized disease compared to metastatic disease using the
significance analysis of microarrays (SAM) method [34]. Based on
these six genes, they classified patients into high- and low-risk
groups with 1-year survival rates of 55% and 91%, respectively.
Our signatures classify patients into high- and low-risk groups with
1-year survival rates of 54% and 76%, respectively (adjuvant six-
gene signature) and 55% and 69%, respectively (non-adjuvant
five-gene signature). Unfortunately, Stratford et al. [18] did not
report a classification accuracy percentage. Most surprisingly,
although patients and methods were different, the six genes
identified in their study and our seven genes share one gene of the
Fos family. As mentioned before, there has hardly been any
overlap among the signatures published so far for one tumor type.
The discovery of FOS in both methods thus highlights its
importance for tumor progression and outcome in pancreatic
cancer, and further underlines the ability of our method to find
reproducible and biologically significant markers.
The influence of NetRank parameters on the results
NetRank depends on a number of parameters (see Materials
and Methods for a full description): the choice of the genes’ initial
values c that spread through the network, the damping factor d
Figure 2. NetRank feature selection outperforms standard feature selection methods. (A) The accuracy of different feature selection
methods for predicting patient outcome was tested on the screening dataset. The NetRank feature selection using a transcription factor network is
shown in red. For smaller training set sizes, our method is superior to all other feature selection methods, reaching an accuracy of 72% in a Monte
Carlo cross-validation. (B) Markers found with NetRank are more accurate than markers described in literature.
doi:10.1371/journal.pcbi.1002511.g002
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PLoS Computational Biology | www.ploscompbiol.org 7 May 2012 | Volume 8 | Issue 5 | e1002511Figure 3. Regulatory network around signature genes. (A) All direct neighbors for the seven candidates STAT3, FOS, JUN, SP1, CDX2, CEBPA,
and BRCA1 (marked yellow). Transcription factors are marked with a dot. Genes reported in the literature associated with pancreatic cancer survival
according to GoGene are represented with larger circles. The absolute correlation coefficient of gene expression with survival in the screening dataset
is shown in red. (B) Selection of the network showing genes that are regulated by FOS and SP1. It contains many literature-associated and highly
correlated genes. (C) Protein–protein interactions among all signature genes, representing physical interactions between the transcription factors
SP1, STAT3, JUN, FOS and the transcription coactivator BRCA1.
doi:10.1371/journal.pcbi.1002511.g003
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and the role of noisy and uninformative genes, which are filtered
out. Next, we investigate NetRank’s dependence on these
parameters.
Choice of genes’ initial values. As mentioned above,
NetRank spreads the correlation of a gene’s mRNA level with
survival time in our dataset through the network (see parameter c
in Materials and Methods). What happens if the value c does not
use this specific dataset-dependent fingerprint, but instead a
constant value so that all genes are a priori equally important–or,
from another perspective, if one only relies on network topology?
We tested this and found a prediction accuracy of 62–65% (+0:3–
1% s.e.m., see Table S4) for all training set sizes, which is
considerably less than the 72% (+1% s.e.m.) maximum accuracy
of the original NetRank. This is interesting since it implies that
although some improvement is already gained by focusing on
network hubs independent of gene correlations, there is indeed
more prognostic information that comes from the use of concrete
expression values linked to clinical data.
Network damping factor. Another important question
regarding the algorithm relates to the optimal choice of the
damping factor d (see Materials and Methods) used to spread
values through the network. Setting d~0 corresponds to no
influence of the network and full influence of the gene expression
data, whereas d~1 corresponds to full network influence and no
influence of the gene expression data. According to [26], Google’s
PageRank uses d~0:85.
To find the optimal d for our dataset, we added an inner cross-
validation loop to our Monte Carlo workflow (see Figure 1, steps
2a to 2d). A value of d~0:3 on the TRANSFAC network of
transcription factors and their regulated targets gave the best
results in terms of predictive accuracy of the identified signature
genes. Is there an intuitive reason why d~0:3 is the best choice?
Unfortunately, there seems to be no optimal damping factor across
different cancer microarray studies. The value d~0:3 is optimal
for this one study. We also have data for optimal d-values in ten
other cancer studies [5,13,33,52–58] and they vary (from 0.1 to
0.9, with 0.3 being the most frequent value). This suggests that in
some cases more distant genes exert a stronger influence. Also, the
incompleteness of current interaction networks implies that the
fraction of disease-relevant genes covered by the network varies
between diseases. For some studies, the network might cover the
particular disease-relevant genes well and for others not. Thus, the
d-value indicates also the match of the network’s coverage and
connectivity to the particular study.
Influence of direct neighbors. A damping factor d~0:3
suggests that the results strongly depend on direct neighbors: The
PageRank can be viewed as an indication of the likely location of a
random surfer who iteratively traverses the network. At each
iteration the surfer makes a step from one node to one of its
neighbors with probability d, while with probability (1{d) he
makes a jump to a random node in the network. In NetRank such
a random node is selected with probability proportional to the
correlation of the corresponding gene expression with patient
survival (given by vector c). With d~0:3, the probability of
making two consecutive steps is 0:3|0:3~0:09. Thus, the final
ranking is obtained with information that comes for more than
90% from initial correlation values and direct neighbors only.
So how does an algorithm perform that considers only direct
neighbors instead of the whole network? In other words, is the
global network structure needed to judge each gene, or is its local
neighborhood sufficient? We implemented a variant of NetRank
that spreads values only to direct neighbors. Each node is ranked
according to the average of the initial node values of its direct
neighbors. To our surprise, as shown in Figure S5, this direct
neighbor variant performed almost identically to the ranking by
Pearson correlation (without network information). Hence, at least
for this study, it is important to also consider distant neighbors.
With a sufficiently large number of training samples, NetRank
nearly always performs best, but the difference to Pearson
correlation and the direct neighbor method becomes sufficiently
small. With few training samples, NetRank and the network only
(constant c value) approach compete for the best accuracy. It
seems that the strength of NetRank is to rely on network topology
when data are sparse and correlation can be misleading, and to
shift to relying on correlation when sufficient data is available.
Choice of network. The results presented here use a
regulatory network, TRANSFAC. We also experimented with
protein interaction data from the Human Protein Reference
Database (HPRD) [39] and co-expressed genes from COX-
PRESdb [40]. Although the protein interaction and co-expression
networks are much larger and could have better coverage, they led
to worse results. This suggests that for outcome prediction direct
regulation is more valuable information than general interaction
or co-expression. In fact, for the ten other cancer outcome studies
we investigated [5,13,33,52–58], a TRANSFAC-based network
gave the best results in seven, and a HPRD-based network in three
of the studies.
Filtering. We initially filtered out low expression and low
variance genes from our microarray data. It is commonly agreed
upon that this is a necessary first step when searching for
discriminative genes in microarray data. But since NetRank is a
network-based, integrative approach, removing genes that could
otherwise provide information for their neighboring nodes is
probably a suboptimal strategy. For NetRank, we therefore keep
all genes, but assign an initial value of zero to those genes that do
not pass the filter. This leads for example to downranking of a
node that has many neighbors with a value of zero, but it also
allows for upranking of a node with an initial value of zero that has
many high value neighbors.
The question if filtering is necessary at all however remains.
One would expect NetRank to be robust against ‘‘noise’’ since it
uses additional network information that can help to detect and
ignore noise. To clarify, our initial filtering actually serves two
purposes. It removes not only noise (genes with low expression that
are most likely not expressed), but also removes uninformative
genes (genes that have low variance and thus cannot be used to
discriminate between any classes in the data). Note that
uninformative genes can be highly expressed – in our data, one
third of the genes have high expression, but low variance.
To separately assess the effect of noisy (low expression) and
uninformative (low variance) genes on the accuracy we ran further
Figure 4. Signature to predict risk in patients with and without adjuvant therapy. (A) Signature to predict risk in patients with adjuvant
therapy. The signature was developed with patients receiving adjuvant therapy separated by their median survival into two groups, a high risk group
with shorter survival and a low risk group with longer survival. A classifier trained with the signature using leave-one-out cross-validation shows a
significant difference between the predicted low and high risk group (p~0:0014, logrank test). (B) Signature to predict risk in patients without
adjuvant therapy. The signature was developed with patients not receiving adjuvant therapy separated by their median survival into two groups, a
high risk group with shorter survival and a low risk group with longer survival. A classifier trained with the signature using leave-one-out cross-
validation shows a significant difference between the predicted low and high risk group (p~0:0065, logrank test).
doi:10.1371/journal.pcbi.1002511.g004
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interesting. When we did remove uninformative genes but not
remove noisy genes, the resulting accuracy was still 71%
(compared to 72% in the original filtering). This suggests that
NetRank is rather robust to noise. However, when we did remove
noisy genes but not remove uninformative genes, the accuracy
dropped to 56%, which suggests that NetRank is not robust at all
with respect to the presence of uninformative genes. Inspection of
the highly ranked genes in this case revealed that the majority of
them were uninformative high expression, low variance genes. As
the top 5–10 genes are used for classification in our SVM, it is not
surprising for the accuracy to drop if more than half of these genes
are uninformative and hence cannot help in classification. A
comparison with the original filtered approach showed that the
previous top-ranked nodes are still found, but that the uninfor-
mative nodes score even higher.
So why does NetRank assign high scores to uninformative
genes? There is a simple explanation: the input for NetRank are
not use gene expression values, but the genes’ correlation with
survival. So besides the network, the basis for ranking is a gene’s
absolute correlation coefficient, not its expression value. When we
plotted the distribution of these correlation coefficients in four
different groups (low/high expression/variance), we found that the
highly expressed uninformative genes had very similar correlation
coefficients compared to informative genes (see Figure S6). This
means that is virtually impossible for NetRank to detect if a gene
will be uninformative for classification, as it can have an equally
good correlation value than an informative gene. The fact that
many highly expressed low variance genes are apparently
correlated with survival suggests that either Pearson correlation
is not an ideal measure here, or that the number of samples is too
small to give a higher correlation signal in the informative genes.
Since Spearman rank correlations show a similar pattern, we
believe that the latter is true and that for this dataset size filtering is
the best strategy.
To summarize, while NetRank is rather robust against noisy low
expression measurements, it is essential to filter out uninformative
genes (i.e. set their initial values to zero) before running NetRank.
Discussion
Here, we present a novel method for identifying prognostic
markers from genome-wide gene expression data. A key feature of
the method is that it judges the relevance of a gene as marker not
only by its expression (or rather the correlation of its expression
with survival), but also by the expression of its neighbors. Thus, it
can detect and therefore avoid markers that correlate with survival
simply by chance or noisy measurements, but not due to an
underlying biological causality. We applied this method to
microarray data from 30 freshly frozen samples of pancreatic
ductal adenocarcinoma and obtained a prognostic marker set of
seven genes. This set showed an accuracy of 72% in predicting the
prognosis of a patient. To ensure validity of this result, we
employed a rigorous Monte Carlo cross-validation procedure. We
then validated these genes using high-throughput immunohisto-
chemistry of samples from surgically resected tumors from an
independent cohort of 412 patients; roughly half of these received
adjuvant therapy. From the marker set we derived a six-gene
signature for patients with adjuvant therapy and a five-gene
signature for patients without adjuvant therapy. Both signatures
improve prediction of patient prognosis compared to the use of
clinical parameters when used for immunohistochemical staining
of the tumor tissue. The additional predictive value of the
signature markers compared to clinical parameters was 9% for
patients with and 6% for patients without adjuvant therapy (as the
best combination of clinical parameters only showed a predictive
accuracy of 61% and 59%, respectively). Whereas the use of
microarrays in clinical practice is limited by the large number of
genes, complicated analytical methods, and the need for fresh-
frozen tissue, RT-PCR or immunohistochemistry of a small
number of proteins can be done routinely in a clinical setting.
Note that the samples were obtained during initial surgery,
before any of the patients received adjuvant therapy. The
expression signatures we identified predicted clinical outcomes
specific for patients with and without adjuvant therapy. These
signatures could be used to stratify patients for adjuvant treatment
of the disease: A patient that is classified as low risk (good
prognosis) by the adjuvant therapy signature should receive
adjuvant chemotherapy treatment, whereas a patient that is
classified as low risk by the no adjuvant therapy signature might
have a longer survival without chemotherapy.
Our signature genes can also help to stratify pancreatic cancer
patients for new therapies. STAT3 was found to be the best single
prognostic marker, with a high expression of STAT3 indicating a
high risk. STAT3 inhibitors might therefore be promising
therapeutic agents. It is known that a large percentage of
pancreatic cancers feature aberrantly activated STAT3 [59]. Very
recently, novel STAT3 phosphorylation inhibitors were demon-
strated to suppress growth in pancreatic cancer cell lines [60].
For breast cancer, an FDA approved microarray-based test that
uses the 70-gene signature by van’t Veer et al. [3] to assess the
metastatic risk in patients with node negative breast cancer is
commercially available and can be utilized clinically. In a validation
study on an independent data set of 307 node-negative breast
cancer patients [23], the 70-gene test was shown to have a sensitivity
of 90% and a specificity of 42%. The accuracy, however, resulted in
50%, which is equivalent to guessing. The reported ROC curve for
predicting time to distant metastases shows the same area under
curve of 68% as our signature for predicting prognosis in patients
with adjuvant therapy (Figure 4A). Using an appropriate cut-off,
our signature also shows a high sensitivity of 83% with a specificity
of 45% (upper right corner of the ROC curve, Figure S4A). It
therefore can be used reliably to identify a group of patients who
seem to benefit from the adjuvant therapy.
Our study emphasizes the benefit of systematic network-based
approaches that incorporate background knowledge for identifying
biologically relevant marker genes. Correlations between gene
expression levels and a clinical variable of interest can arise simply
by chance, without any underlying biological cause, especially with
few patient samples. One example for such a spurious correlation
in our screening dataset is the HBA1 gene, which encodes for
hemoglobin alpha, and which showed a strong negative correla-
tion with survival. Although HBA1 would have been a candidate
marker when ranked merely by correlation, it was not ranked
among the top ten markers by NetRank. Since we found the idea
of a cancer tissue expressing hemoglobin interesting and worth
exploring further, we decided to include HBA1 in the immuno-
histochemistry validation. However, immunohistochemical stain-
ing for hemoglobin in the validation dataset was incapable of
defining significantly different risk groups. In addition, adding
HBA1 to our signatures did not improve, but impaired their
predictive accuracies. We conclude that the strong negative
correlation of HBA1 expression levels with survival time in the
screening dataset might have been caused by chance and not by
any underlying biologically relevant causality. Network-based
methods such as NetRank can add such causality for example in
the form of known gene regulatory networks, resulting in the
identification of markers that are more likely to be truly relevant.
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network-based approaches [61]. Their study demonstrated that
markers based on protein interaction subnetworks are first more
reproducible than individual marker genes and second can
improve classification accuracy for the van’t Veer breast cancer
dataset by 8% compared to the original 70 genes [3]. A further
approach documenting the usefulness of networks employed
PageRank to identify genes cross-talking between already
published cancer genes [62].
During the progress of our study, another study [63] was
published which used PageRank on protein interaction networks
to improve recursive feature elimination for support vector
machine learning. They found that this improved the prediction
of ERBB2 status and relapse in breast cancer. However, neither of
these two studies validated their genes on an external patient
cohort to demonstrate the validity of markers found with
PageRanking based on biological networks. Moreover, we found
that the use of transcription factor–target networks yields more
accurate signatures than the use of protein interactions networks in
cancer outcome studies.
The use of background knowledge in order to get more robust
and more biologically meaningful signatures comes at a price. It is
in the nature of the NetRank algorithm to favor genes with many
connections, since they can increase their ranking, whereas
uncharacterized genes with no connections cannot. Hence, marker
genes found with NetRank are more likely to be well known and
well-described in the literature and less likely to be previously
uncharacterized. We also found that the predictive accuracy of the
immunohistochemistry -based markers was lower than that of the
microarray-based markers. One potential bias stems from the
different design of tissue microarrays, which vary in the number of
cores per case, core size, and density. In addition, the semi-
quantitative evaluation of the immunohistochemical staining tends
to be less accurate and less objective than microarray-based gene
expression profiling.
In conclusion, the expression signatures we identified predicted
clinical outcomes in patients with surgically resected pancreatic
ductal adenocarcinoma specific for patients with and without
adjuvant therapy. Since these signatures could be used to stratify
patients for adjuvant treatment of the disease, they are a potential
additional piece of information in clinical decision making and can
help to reduce costs, improve patient survival, and quality of life.
Materials and Methods
Screening dataset
Two hundred forty-four freshly frozen tissue samples of
pancreatic adenocarcinoma were obtained from surgical speci-
mens from patients who underwent operations between 1996 and
2007 at German university hospitals in Berlin, Dresden, Heidel-
berg, Mannheim, Munich, and Regensburg. Informed consent
was obtained from all patients included in this study. From each of
the frozen tissue samples, 4 mm slides were obtained, stained with
hematoxylin and eosin, and re-evaluated by a pathologist (G. K.)
experienced in pancreato-biliary pathology. Of these, 56 tissue
samples contained tumorous tissue without any contamination
from normal acini or islets and had suitable RNA quality. Of
these, 30 were obtained from patients without any adjuvant
therapy, and were used as the screening dataset. The clinical
characteristics of this dataset are given in Table 1.
RNA preparation and array hybridization of the
screening dataset samples. Total RNA was prepared from
10 mm thick sections using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s recommendations. The
quality of the prepared RNA was controlled using the Agilent
RNA 6000 Pico Kit (Agilent, Bo ¨blingen, Germany). Only RNA
samples with more than 3 ng/ml RNA and an RNA integrity
number greater than 4 were subjected to further analysis. From
each sample 100 ng was used for cDNA synthesis and in vitro
transcription-based amplification according to the Affymetrix
GeneChip Two-Cycle Target Labeling and Control Kit (Affyme-
trix, Santa Clara, USA). Hybridization and detection of the
labeled aRNA on the Affymetrix GeneChip Human Genome
U133 Plus 2.0 (Affymetrix, Santa Clara, USA) were performed as
recommended by the manufacturer.
Preprocessing and filtering of screening dataset
microarray raw data. Affymetrix raw probe level intensity
(CEL) files were background-corrected, normalized, and summa-
rized using RMA [64]. The MIAME compliant data were
deposited in the ArrayExpress database under the accession
number E-MEXP-2780. Since our goal was to find a small
number (five to ten) of reliable markers, we wanted to make sure
that any candidate markers that we test further do not fall into one
the categories of (i) low variance between all samples and therefore
not discriminative, (ii) de facto not expressed, or (iii) expressed at
very low levels and thus not reliably measured in our microarray
data. This is achieved by the filtering steps described in the
following. Note that for NetRank, filtering out meant actually not
removing, but setting intial values to zero in order to prevent loss
of edges from the network due to node removal.
First, to remove noise from genes with low expression, probe
sets with a mean expression below 6 on the log2 scale were filtered
out from the dataset. Out of an initial 54,675 probe sets
(measuring the expression of 20,111 genes), *30,000 remained
after this filtering. Second, genes whose expression shows little
variation between patients are not informative as they cannot
discriminate between patient groups. We therefore filtered out
probe sets with a standard deviation below 0.5 on the log2 scale.
This further reduced the number of probe sets to *15,000. Third,
we decided to keep for each gene only the probe set with the
highest mean expression over all patients. We generally found a
high correlation between probe sets reporting for the same gene.
Keeping only the one probe set with the highest mean expression
for each gene reduced the number of probe sets to 7,871
(measuring the expression of 7,871 genes). This is the size of the
dataset that was used for all subsequent analyses. For NetRank, in
order not to lose edges due to missing nodes, the size of the dataset
was 20,111, with all except the 7,871 genes initialized with zero.
Quantitative real-time PCR (RT-PCR) of the screening
dataset samples. RNA from the first amplification cycle was
reverse transcribed into cDNA. One nanogram of cDNA was used
for each TaqMan assay (Applied Biosystems, Weiterstadt,
Germany). RT-PCR was performed using the TaqMan Universal
PCR Master Mix (Applied Biosystems, Weiterstadt, Germany)
according to the manufacturer’s instructions. Gene expression of
prognostic signature genes was quantified by the relative expression
values using the following gene specific TaqMan Gene Expression
Assays: BRCA1 (Hs01556193_m1), FOS (Hs01119266_g1), CDX2
(Hs01078080_m1), STAT3 (Hs00234174_m1), HBA2 (Hs00361191_g1),
HBB (Hs00758889_s1), SRD5A1 (Hs00602694_mH), SP1
(Hs00293689_s1), JUN (Hs00277190_s1), USF1 (Hs00273038_m1),
and CEBPA (Hs00269972_s1).
Validation dataset
The validation dataset consisted of surgically resected PDAC
samples from 517 patients who underwent operation between
1991 and 2008 at university hospitals in Berlin, Dresden, Jena, and
Regensburg, Germany. Informed consent was obtained from all
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years by telephone inquiries, registry at cancer centers, and
residents’ registration offices. Out of the 517 patients, 105 were
excluded because of missing data. The clinical characteristics of
this dataset are given in Table 1. After the completion of this
study we became aware of the fact that two patients (without
adjuvant treatment) were present in both our screening and
validation data set. To ensure that this caused no bias in our
results, these two patients were excluded from all test sets in the
validation analysis presented here.
Immunohistochemistry of the validation dataset. For
immunohistochemical analysis, tissue microarrays with 1–4 cores
per patient and with core sizes of 0.6 mm–2 mm were prepared
using all the samples. The total number of cores was 1,696. Five
mm thick sections were prepared using silanized slides (Menzel
Gla ¨ser, Braunschweig, Germany). Immunohistochemistry was
performed using the Benchmark System (Ventana, Illkirch,
France) with the following antibodies and protocols: anti CDX2
(030044, DCS Innovative Diagnostik-Systeme, Hamburg, Ger-
many, dilution 1:30, UltraView DAB, CC1), anti c-Fos (sc-253,
Santa Cruz Biotechnology, dilution 1:100, pretreatment with
heat), anti SP1 (sc-14027, Santa Cruz Biotechnology, dilution
1:100, pretreatment with heat), anti CEBPA (sc-61, Santa Cruz
Biotechnology, dilution 1:100, pretreatment with heat), anti
STAT3 (9139, Cell Signaling Technology, Frankfurt, Germany,
dilution 1:400, UltraView DAB, CC1), anti Jun (ab31367, Abcam,
Cambridge, UK, dilution 1:100, UltraView DAB, CC1), and anti
BRCA1 (Calbiochem, dilution 1:30, pretreatment with heat and
enzymes). Afterwards the slides were briefly counterstained with
hematoxylin. The staining was evaluated semi-quantitatively by a
pathologist (G.K., D.A., or T.K.) without knowledge of the
histopathological or molecular data into either four grades
(negative, faint, moderate, and strong) or into percentages (0–
100%) of strongly stained nuclei. For classification, the expression
of each immunohistochemistry marker was dichotomized using
the median value (median grade or median percentage) as a cut-
off, resulting in two possible levels (low or high) for each marker.
Classification procedures
Support vector machines are powerful supervised machine
learning algorithms for classification problems [65–67]. We used a
support vector machine to classify pancreatic tumors samples into
poor or good prognosis groups based on the expression levels of
selected genes. Here, we used the LIBSVM implementation as
provided in the R package e1071 (version 1.5-18, obtained July
2008 from http://cran.r-project.org/web/packages/e1071/). The
expression level of each gene was used as an independent feature
to train the classifier. No kind of aggregation was used. All feature
selection and machine learning steps were subjected to Monte
Carlo cross-validation, which is a recommended and relatively un-
biased evaluation strategy [22,35] described in the following.
Monte Carlo cross-validation workflow. To get a robust
estimate on the classification error rate, we adopted the multiple
random validation strategy described by [22]. Given a fixed
signature size n and a feature selection method, the following steps
were repeated 1,000 times (see Figure 1):
1. The starting point is the screening dataset after filtering,
consisting of a gene expression matrix with 7,871 features
(rows) and 30 patient samples (columns). For NetRank, we
additionally included genes (features) that did not pass filtering
with their initial values set to zero.
2. The data are randomly split into training and test sets. The
splitting is balanced such that the numbers of poor and good
samples in the test set are either equal or differ by at most one.
This is to ensure that there is no over-representation of one of
the groups in the training set.
3. Using the training set data only, features are ranked according
to a feature selection method (see below).
4. The top-ranked n features are selected. These features become
the signature.
5. The signature from the training set is used to train a classifier
on the sample outcome, using the training set expression values
of the signature genes as input.
6. The classifier is used to predict the outcome of the unseen test
set patients.
7. The predicted outcome is compared with the true outcome.
The fraction of correctly predicted patients defines the
accuracy.
For NetRank, additional steps are taken between step 2 and step
3, which are explained the NetRank section below. The overall
classification accuracy is the average of all repeated workflow
accuracies. In order to ensure maximally comparable results, the
random splits into training and test sets were carried out once and
the sets were recorded. Thus, the exact same training and test sets
were used for each method.
Calculation of prediction accuracy. Throughout the text,
we use accuracy as the percentage of correctly classified samples, i.
e. the sum of true positives and true negatives divided by the sum
of true positives, false positives, true negatives, and false negatives.
Feature selection methods. Patients in the screening
dataset were divided into two groups based on median survival
time. The poor prognosis group consisted of patients who survived
less than or equal to the median survival time, whereas the good
prognosis group consisted of patients who survived longer than the
median survival time. To select genes for a prognostic signature,
the following methods for selecting genes were tested: (i) fold
change, as defined by the ratio of mean gene expression in one
group over the other group, (ii) the Student’s t-statistic, (iii) the
Pearson correlation coefficient of gene expression with survival
time of the patient, and the Spearman rank correlation coefficient
of gene expression with survival time of the patient, (iv) the SAM
(Significance Analysis of Microarrays) method [34], and (v) our
own NetRank algorithm. We also included selecting genes
randomly.
The NetRank algorithm for network-based gene ranking
For ranking of genes, NetRank combines the correlation of a
gene’s expression level with the survival time of the patient with a
network of known gene–gene relationships. The ranking can be
computed iteratively. Here, we follow the notation and imple-
mentation in [37]:
rn
j ~(1{d)cjzd
X N
i~1
wijrn{1
i
degi
1ƒjƒN ð1Þ
Here rn
j denotes the ranking of page j after n iterations, W[R
N|N
is a symmetric adjacency matrix for the gene network, so
wij~wji~1 if genes i and j are connected, and wij~wji~0
otherwise.~ c c is a vector of absolute Pearson correlation coefficients
of gene expression values with the patient survival time, and
d[(0,1) is a fixed parameter describing the influence of the
network on the rank of a page. Setting d~0 corresponds to no
influence of the network and full influence of the gene expression
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network and no influence of the gene expression data. The value
d~0:85 appears to be used by Google [26]. The rank of a gene
depends on the rank of all genes that link to it. Scaling by 1=degi in
the summation ensures that each gene has equal influence in the
voting procedure. Each gene gets a rank of 1{d automatically
and also gets d times the votes given by other genes.
The iteration to convergence in (1) corresponds to solving the
equation
(I{dWTD{1)~ r r~(1{d)~ c c ð2Þ
where I is the identity matrix, WT is the transpose of W, and
D~diag(degi). With the choice of d~0 (no influence of the
network, full influence of the gene expression data), equation (2)
has the solution~ r r~~ c c. That is, the rank of a gene solely depends on
the correlation of its expression with survival time. For d~1 (full
influence of the network, no influence of the gene expression data),
equation (2) becomes
(I{WTD{1)~ r r~~ 0 0 ð3Þ
Monte Carlo cross-validation workflow for NetRank. The
parameter d is set as part of the Monte Carlo cross-validation
workflow. For NetRank, we added an additional inner cross-
validation loop (see Figure 1, steps 2a to 2d). In this inner cross-
validation, a part of the training set samples were set aside, and
different values of d ranging from 0 to 1 in steps of 0.1 were used to
run NetRank on the remaining training set samples. Accuracies of
the top-ranked genes were then tested on the samples previously set
aside. As a result of the inner cross-validation, one d was chosen
and used once for deriving a signature based on the whole training
set, and evaluating its accuracy on the test set. It is important to
note that no information of the test set is used for selecting d, so the
choice of a value for d in the inner cross-validation does not rely on
any prediction accuracy in the test set data. We found that a value
of d~0:3 on the TRANSFAC network of transcription factors and
their regulated targets gave the best results in terms of predictive
accuracy of the identified signature genes. R code is available from
the authors upon request.
Network datasets. For NetRank, results were based the
TRANSFAC network which is defined by all human transcription
factor–target pairs as provided in the TRANSFAC Suite 2008
[38]. Further networks tested were the HPRD network where
genes are connected if there is a known interaction of their
proteins in the Protein Reference Database (HPRD) [39], and the
COXPRESdb network where genes are connected if their co-
expression correlation coefficient as reported in the in the
COXPRESdb database [40] is above 0.25. COXPRESdb
contains co-expression values for all pairs of 19,777 human genes
derived from a wide number of publicly available microarray
datasets.
Literature-based markers
To identify genes mentioned in the literature as prognostic
immunohistochemistry markers for pancreatic cancer, we used
GoGene [68] and combined the results of queries ‘‘pancrea*
prognos* immunohisto* paraffin’’ and ‘‘pancrea* survival im-
munohisto* paraffin’’. GoGene performs a PubMed query with
the search term and then identifies gene names in the abstracts
reported by PubMed. Table S2 shows the literature genes with
the PubMed IDs of the abstracts in which they were found.
Supporting Information
Figure S1 Survival time distribution in ten published
cancer outcome studies. (A)–(J) Histograms of survival times
from ten published studies using microarray data from cancer
patients for outcome prediction. For studies which define two
prognosis groups, these groups are indicated by color (red, poor
prognosis and blue, good prognosis). The dashed vertical line
indicates the median.
(PDF)
Figure S2 Examples of immunohistochemical staining
of the marker candidates. Antibody staining intensities were
scored semi-quantitatively by a pathologist using four grades of
negative ({), faint (z), moderate (zz), and strong (zzz)
staining.
(PDF)
Figure S3 Survival by adjuvant therapy. Out of 412
patients in the validation dataset, 172 patients who received
adjuvant therapy had a lower 5-year-survival than the 240 patients
who did not receive adjuvant therapy, although the difference is
not significant (p~0:2, logrank test).
(PDF)
Figure S4 Receiver operating characteristic curves of
signatures to predict risk. (A) Signature to predict risk in patients
with adjuvant therapy. The signature was developed with patients
receiving adjuvant therapy separated by their median survival into
two groups, a high risk group with shorter survival and a low risk
group with longer survival. The signature consisted of the marker
proteins STAT3, FOS, JUN, CDX2, CEBPA, and BRCA1. The
receiver operating characteristic (ROC) curve of a classifier trained
with this signature shows an area under the curve of 68% using leave-
one-out cross-validation. (B) Signature to predict risk in patients
without adjuvant therapy. The signature was developed with patients
not receiving adjuvant therapy separated by their median survival
into two groups, a high risk group with shorter survival and a low risk
group with longer survival. The signature consisted of the marker
proteins STAT3, JUN, SP1, CDX2, and BRCA1. The ROC curve
of a classifier trained with this signature shows an area under the curve
of 59% using leave-one-out cross-validation.
(PDF)
Figure S5 Comparison of NetRank with a direct neigh-
bor algorithm. The plot shows the accuracy of a direct neighbor
approach that only takes direct neighbors into account (as opposed
to NetRank, which considers all nodes in the network) on the
TRANSFAC network with different training set sizes. The direct
neighbor approach performs almost identically to the Pearson
correlation method (shown here for comparison). See below for a
description of the direct neighbor method.
(PDF)
Figure S6 Distribution of expression levels and correla-
tion with survival in four distinct subsets of the full
screening dataset. (A) Histogram (density) of gene expression
levels. Our filtering keeps only the high expression, high variance
genes (red curve). Sizes of the four subsets are shown in the upper
right. (B) Histogram (density) of absolute Pearson correlation
coefficients of gene expression levels with patient survival. Since the
red and the blue curve have very similar distribution, ranking by
correlation (which is the starting point for our NetRank algorithm)
will allowselectionofuninformative,lowvariance genes(blue curve)
that will impair prediction accuracy when included in a classifier.
Hence, it is important to filter such genes out.
(PDF)
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ies on finding predictive signatures published in high-
impact journals. The studies were published in Science, Nature,
Nature Medicine, PNAS, PLoS Medicine, Cancer Cell, Lancet,o rNew
England Journal of Medicine. Some studies exhibit considerable flaws
in methodology, as pointed out in the notes at the table bottom.
(PDF)
Table S2 Fifty-one immunohistochemistry markers
prognostic for survival in pancreatic cancer, found with
a literature search.
(PDF)
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